Uterine Serous Carcinoma clinical trials at University of California Health
1 research study open to eligible people
open to eligible females ages 18 years and up
This is a Phase 2 study to evaluate the clinical activity and safety of ZN-c3 (azenosertib) in adult women with recurrent or persistent uterine serous carcinoma (USC).
at UC Irvine